Stryker (SYK) announced it has received FDA 510(k) clearance for the Incompass Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker’s Inbone and Infinity systems into a single solution for total ankle replacement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker price target raised to $455 from $443 at Citi
- Stryker announces FDA 510(k) clearance for OptaBlate
- Stryker Shareholders Approve Amendments at Annual Meeting
- Stryker’s Strategic Moves and Strong Financial Outlook Justify Buy Rating with $435 Price Target
- Stryker price target raised to $400 from $390 at Truist